<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00172809</url>
  </required_header>
  <id_info>
    <org_study_id>940209</org_study_id>
    <nct_id>NCT00172809</nct_id>
  </id_info>
  <brief_title>Interferon Treatment for Patients With Chronic Hepatitis C and End Stage Renal Disease</brief_title>
  <official_title>A Pilot Study in Comparing the Efficacy and Safety of Peginterferon Alfa-2a and Interferon Alfa-2a in Treating Patients With End Stage Renal Disease and Chronic Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The treatment response with conventional interferon alpha alone in patients with end stage&#xD;
      renal disease and chronic hepatitis C is about 33-39%. However, the drop-out rate is&#xD;
      17-29.6%. Pegylated interferon alpha, a newly developed form of interferon with superior&#xD;
      pharmacokinetic profiles, has not been used to treatment these patients. We expect the better&#xD;
      treatment response treated with peginterferon alpha than conventional interferon. In&#xD;
      addition, we also observe the safety of the two drugs during the study. The goal of the study&#xD;
      is to compare the efficacy and safety of the two different treatment regimens in patients&#xD;
      with chronic hepatitis C and end stage renal disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic hepatitis C virus (HCV) infection is common among patients with end stage renal&#xD;
      disease (ESRD), with the reported prevalence ranging from 8 to 20% in dialysis patients in&#xD;
      developed world. In Taiwan, the estimated prevalence of HCV infection in patients with ESRD&#xD;
      who maintain hemodialysis ranges from 20 to 24.7%. Although most studies have provided mild&#xD;
      to moderate disease activity and a high proportion of normal alanine aminotransferase (ALT)&#xD;
      levels, the frequency of bridging hepatic fibrosis or cirrhosis ranges from 5 to 32%. Several&#xD;
      studies have shown that chronic hepatitis C adversely affects the survival in patients with&#xD;
      ESRD. After renal transplantation, recipients with HCV have an increased risk of&#xD;
      liver-related mortality and morbidity compared with those without HCV. Therefore, eradication&#xD;
      of HCV can improve clinical outcome in dialysis patients as well as in patients awaiting&#xD;
      renal transplantation.&#xD;
&#xD;
      Combined interferon and ribavirin is the standard therapy in HCV-infected patients with&#xD;
      normal renal function. However, ribavirin, which is cleared by the kidneys, may cause severe&#xD;
      hemolytic anemia and be dangerous in dialysis patients. Two recent meta-analyses showed that&#xD;
      the sustained virological responses were (SVR) 39% and 33%; the drop-out rate were 17% and&#xD;
      29.6% in HCV-infected dialysis patients treated with interferon-alpha 3 MU thrice weekly of&#xD;
      varied duration. The response and the drop-out rate were higher than that reported in&#xD;
      HCV-infected patients with normal renal function (SVR of 7-16% by interferon-alpha 3 MU&#xD;
      thrice weekly for 24 weeks; drop-out rate of 5-9%) due to a lower interferon clearance rate.&#xD;
&#xD;
      Peginterferon alpha-2a (40KD) is a modified form of interferon alpha-2a consisting of a&#xD;
      branched polyethylene glycol (PEG) chain covalently bound to interferon alpha-2a. A better&#xD;
      response of peginterferon alpha-2a than interferon alpha-2a has been demonstrated in&#xD;
      HCV-infected patients with normal renal function, either combined with ribavirin or not, due&#xD;
      to the superior pharmacokinetic profiles. The clearance of peginterferon alpha-2a for ESRD&#xD;
      patients was about 30-40% lower than that in healthy subjects. A similarly pharmacokinetic&#xD;
      profile of peginterferon alpha-2a is observed with 135 μg weekly in dialysis patients&#xD;
      compared with 180μg weekly in patients with normal renal function.&#xD;
&#xD;
      We expect that peginterferon alpha-2a is superior to interferon alpha-2a in achieving an&#xD;
      increased SVR and decreased drop-out rate in dialysis patients. The goal of the study is to&#xD;
      compare the efficacy and safety of the two different treatment regimens in patients with&#xD;
      chronic hepatitis C and end stage renal disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained histological response and sustained virological response 6 months after the completion of the intervention</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The overall tolerance of the two different regimens and the comparison of the rates of side effects</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Peginterferon alfa-2a (Pegasys, Hoffmann-LaRoche) 135 ug/week for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Interferon alfa-2a (Roferon, Hoffmann-LaRoche) 3 MU tiw for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a</intervention_name>
    <description>Peginterferon alfa-2a 135 ug/week for 24 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Pegasus 135 ug/syringe</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon alfa-2a</intervention_name>
    <description>Interferon alfa-2a 3 MU tiw for 24 weeks</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Roferon 3 MU/syringe</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 to 65 years old&#xD;
&#xD;
          -  Creatinine clearance (Ccr) &lt; 10 ml/min/1.73 m2&#xD;
&#xD;
          -  Receiving regular hemodialysis&#xD;
&#xD;
          -  Anti-HCV (Abbott HCV EIA 2.0, Abbott Diagnostic, Chicago, IL) positive &gt; 6 months&#xD;
&#xD;
          -  Detectable serum HCV-RNA (Cobas Amplicor HCV Monitor v2.0, Roche Molecular Systems,&#xD;
             Pleasanton, CA) with dynamic range 600~&lt;500,000 IU/ml&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Neutropenia (neutrophil count, &lt;1,500/mm3)&#xD;
&#xD;
          -  Thrombocytopenia (platelet &lt;90,000/ mm3)&#xD;
&#xD;
          -  Co-infection with HBV or HIV&#xD;
&#xD;
          -  Chronic alcohol abuse (daily consumption &gt; 20 g/day)&#xD;
&#xD;
          -  Decompensated liver disease (Child classification B or C)&#xD;
&#xD;
          -  Neoplastic disease&#xD;
&#xD;
          -  An organ transplant&#xD;
&#xD;
          -  Immunosuppressive therapy&#xD;
&#xD;
          -  Poorly controlled autoimmune diseases, pulmonary diseases, cardiac diseases,&#xD;
             psychiatric diseases, neurological diseases, diabetes mellitus&#xD;
&#xD;
          -  Evidence of drug abuse&#xD;
&#xD;
          -  Unwilling to have contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen-Hua Liu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine, National Taiwan Univeristy Hospital, Yun-Lin Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Taiwan University Hospital, Yun-Lin Branch</name>
      <address>
        <city>Douliou</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther. 2003 Dec;18(11-12):1071-81. Review.</citation>
    <PMID>14653826</PMID>
  </reference>
  <reference>
    <citation>Russo MW, Goldsweig CD, Jacobson IM, Brown RS Jr. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol. 2003 Jul;98(7):1610-5. Review.</citation>
    <PMID>12873587</PMID>
  </reference>
  <reference>
    <citation>Huraib S, Iqbal A, Tanimu D, Abdullah A. Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. Am J Nephrol. 2001 Nov-Dec;21(6):435-40.</citation>
    <PMID>11799259</PMID>
  </reference>
  <reference>
    <citation>Casanovas-Taltavull T, Baliellas C, Benasco C, Serrano TT, Casanova A, Pérez JL, Guerrero L, González MT, Andres E, Gil-Vernet S, Casais LA. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation. Am J Gastroenterol. 2001 Apr;96(4):1170-7.</citation>
    <PMID>11316166</PMID>
  </reference>
  <reference>
    <citation>Tokumoto T, Tanabe K, Ishikawa N, Simizu T, Oshima T, Noguchi S, Gouya N, Nakazawa H, Hashimoto E, Fuchinoue S, Hayashi N, Toma H. Effect of interferon-alpha treatment in hemodialysis patients and renal transplant recipients with chronic hepatitis C. Transplant Proc. 1999 Nov;31(7):2887-9.</citation>
    <PMID>10578327</PMID>
  </reference>
  <reference>
    <citation>Huraib S, Tanimu D, Romeh SA, Quadri K, Al Ghamdi G, Iqbal A, Abdulla A. Interferon-alpha in chronic hepatitis C infection in dialysis patients. Am J Kidney Dis. 1999 Jul;34(1):55-60.</citation>
    <PMID>10401016</PMID>
  </reference>
  <reference>
    <citation>Djordjević V, Kostić S, Stefanović V. Treatment of chronic hepatitis C with interferon alpha in patients on maintenance hemodialysis. Nephron. 1998;79(2):229-31.</citation>
    <PMID>9647511</PMID>
  </reference>
  <reference>
    <citation>Simsek H. Interferon-alpha treatment of haemodialysis patients with chronic viral hepatitis and its impact on kidney transplantation. Nephrol Dial Transplant. 1996 May;11(5):912-3.</citation>
    <PMID>8671933</PMID>
  </reference>
  <reference>
    <citation>Raptopoulou-Gigi M, Spaia S, Garifallos A, Xenou P, Orphanou H, Zarafidou E, Petridou P, Vrettou H, Vagionas G, Galaktidou G, et al. Interferon-alpha 2b treatment of chronic hepatitis C in haemodialysis patients. Nephrol Dial Transplant. 1995 Oct;10(10):1834-7.</citation>
    <PMID>8592590</PMID>
  </reference>
  <reference>
    <citation>Casanovas Taltavull T, Baliellas C, Sesé E, Iborra MJ, Benasco C, Andrés E, González MT, Gil-Vernet S, Casanova A, Casais LA. Interferon may be useful in hemodialysis patients with hepatitis C virus chronic infection who are candidates for kidney transplant. Transplant Proc. 1995 Aug;27(4):2229-30.</citation>
    <PMID>7652784</PMID>
  </reference>
  <reference>
    <citation>Ozyilkan E, Simşek H, Uzunalimoğlu B, Telatar H. Interferon treatment of chronic active hepatitis C in patients with end-stage chronic renal failure. Nephron. 1995;71(2):156-9.</citation>
    <PMID>8569947</PMID>
  </reference>
  <reference>
    <citation>Barril G, Schez Tomero JA, Garcia Buey L, Motellon JL, Bernis C, Traver JA. Response to alpha 2B interferon (IFN) treatment in a haemodialysis patient with chronic hepatitis C. Nephrol Dial Transplant. 1994;9(9):1354-5. Erratum in: Nephrol Dial Transplant 1994;9(12):1850.</citation>
    <PMID>7816309</PMID>
  </reference>
  <verification_date>June 2007</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>March 5, 2008</last_update_submitted>
  <last_update_submitted_qc>March 5, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2008</last_update_posted>
  <responsible_party>
    <name_title>National Taiwan University Hospital</name_title>
    <organization>National Taiwan University Hospital</organization>
  </responsible_party>
  <keyword>Chronic Hepatitis C</keyword>
  <keyword>End stage renal disease</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Interferon</keyword>
  <keyword>Pegylated interferon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

